Explore tweets tagged as #Axogen
$AXGN +6.3% [Axogen shares jumped in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.] https://t.co/t4mDbzHc5d
0
1
1
Axogen $AXGN is popping premarket, after the FDA approved its Avance Nerve Graft, a human tissue based implant to repair damaged peripheral nerves without a second harvest surgery. The OK sets up to 12 years of U.S. exclusivity, with biologic labeled sales targeted for early Q2
1
5
27
BREAKING NEWS Axogen completes marketing submission for Avance Nerve Graft https://t.co/fwPz56ws3B
0
1
0
Oral and maxillofacial surgeons may encounter nerve deficits with myriad causes, including dentoalveolar surgery and tumor resection. Join Axogen at AACMFS April 30 – May 4 in Baltimore to discuss with our nerve experts.
0
1
5
Axogen $AXGN Shares Gain After Receiving FDA Approval of Treatment for Peripheral Nerve Discontinuities
0
1
2
A huge success! Our first Peripheral Nerve Course brought residents & faculty together for hands-on dissections, expert lectures, and rooftop lunches. Led by Dr. Yarema Bezchlibnyk with guest Dr. Nicholas Boulis. Thanks to Dr. Jay Kumar & Axogen for organizing and sponsoring!
0
0
4
$AXGN damnit - stopped out a bit ago Shares of Axogen climbed after the company said the U.S. Food and Drug Administration approved its biologics license application for Avance. Axogen, which develops technologies for nerve regeneration and repair, said late Wednesday that
While 95% on here bemoan tech, we have a whole bull mkt in other areas $AXGN a beast - they got me out a week ago Friday unfort!
0
1
2
AxoGen ’Has Truly Differentiated Products’ - Citizens
0
0
0
$AXGN - Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
0
0
1
This week, the FDA approved a new tissue therapeutic! @axogen announced that the FDA approved AVANCE, an acellular nerve scaffold used to treat sensory, mixed, and motor peripheral nerve discontinuities. https://t.co/iPUBzZNTgh
#TissueTherapeutics #TissueEngineering
0
3
5
$AXGN surged 23%! Axogen's Neural Repair Revolution Takes Off: Q3 Revenue Up 23.5%, BLA Approval Countdown 35 Days – “Biotech Surge Alert!” Axogen ( $AXGN ) earnings report explodes: Q3 revenue of $60.1 million (+23.5%), adjusted EPS of $0.12 (71% above expectations), EBITDA of
0
0
0
The countdown is on as we are only 10 days away from #PREPPED24 that will be held in conjunction with the ACEPS Winter Meeting in St. Louis! We want to thank all the organizers, partners and co-sponsors! @WashUPlastics
@ACEPSedu
@connectmed
@acera_lnc
@axogen
#MEDED
0
2
6
.@axogen's #Avance secures @FDADeviceInfo approval for nerve repair https://t.co/i2PDrYprQc
#medtech
0
0
0
Axogen is excited to see our fellows this weekend in Phoenix for the FULL Best Practices in Upper Extremities course. If you are interested in attending a future event, visit https://t.co/6hdoeCt5CM
0
1
2
Missed #AxogenInvestorDay? 🎥 Watch CEO Michael Dale & our leadership team discuss the Axogen nerve repair algorithm, growth strategy & financial outlook. See how we’re working to make nerve care the expected standard & drive impact. Replay available now: https://t.co/fyTXkMRs2G
0
1
2
$AXGN - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
0
0
0
$AXGN - Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)
0
1
3